Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) Director Riad Hussein El-Dada sold 175,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $0.23, for a total transaction of $40,250.00. Following the completion of the transaction, the director directly owned 175,000 shares of the company’s stock, valued at approximately $40,250. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Greenland Mines Ltd. Common Stock Price Performance
Shares of Greenland Mines Ltd. Common Stock stock opened at $0.26 on Friday. The firm has a market cap of $35.35 million, a P/E ratio of -0.80 and a beta of 6.94. The firm has a 50 day simple moving average of $0.38 and a 200 day simple moving average of $0.39. Greenland Mines Ltd. Common Stock has a fifty-two week low of $0.21 and a fifty-two week high of $1.65.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.15) EPS for the quarter.
Institutional Trading of Greenland Mines Ltd. Common Stock
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings upgraded Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 9th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Greenland Mines Ltd. Common Stock currently has an average rating of “Sell”.
Check Out Our Latest Report on GRML
Greenland Mines Ltd. Common Stock Company Profile
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Read More
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
